Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions

Journal of the Formosan Medical Association

Volumn 109, Issue 5, 2010, Pages 362-368

  Shao, Yu Yun ^a   Hu, Fu Chang ^a   Liang, Jin Tung ^a   Chiu, Wen Tzu ^a   Cheng, Ann Lii ^a   Yang, Chih Hsin ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chemotherapy; Drug hypersensitivity; Oxaliplatin

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; GRANISETRON; OXALIPLATIN; RANITIDINE; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ANAPHYLACTIC SHOCK; ARTICLE; BILIARY TRACT CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHILL; COLORECTAL CANCER; CONSCIOUSNESS DISORDER; CORTICOSTEROID THERAPY; DIGESTIVE SYSTEM DISEASE; DOSE RESPONSE; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HYPERTENSION; JEJUNUM CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NASOPHARYNX CARCINOMA; OUTPATIENT; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PREMEDICATION; PROVOCATION TEST; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SKIN MANIFESTATION; STOMACH CANCER; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 77955901055     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(10)60064-2     Document Type: Article

References (23)

1. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-9.
2. Thomas RR, Quinn MG, Schuler B, et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003;97: 2301-7. (Pubitemid 36444076)
3. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. (Pubitemid 38702845)
4. Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003; 89:477-81. (Pubitemid 37026428)
5. Gowda A, Goel R, Berdzik J, et al. Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 2004;18:1671-84.
6. Kim BH, Bradley T, Tai J, et al. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 2009;76:231-8.
7. Polyzos A, Tsavaris N, Gogas H, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 2009;76:36-41.
8. Shao YY, Hong RL. Fatal thrombocytopenia after oxaliplatinbased chemotherapy. Anticancer Res 2008;28:3115-7.
9. Stahl M, Koster W, Wilke H. Reaction after oxaliplatinprevention with corticosteroids? Ann Oncol 2001;12:874.
10. Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006; 17:259-61. (Pubitemid 43160115)
11. Lenz G, Hacker UT, Kern W, et al. Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anticancer Drugs 2003;14:731-3. (Pubitemid 37357697)
12. Lee MY, Yang MH, Liu JH, et al. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 2007; 15:89-93.
13. National Cancer Institute U.S.: Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, 2006. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm[Date accessed: Mar 1, 2009]
14. de Vries RS, Mattijssen EJ, van Sorge AA. Serious delayed hypersensitivity reaction to oxaliplatin. Ann Oncol 2006; 17:1723-4. (Pubitemid 44680899)
15. Saunders MP, Denton CP, O'Brien ME, et al. Hypersensitivity reactions to cisplatin and carboplatin - a report on six cases. Ann Oncol 1992;3:574-6.
16. Onoyama Y, Umezu T, Kuriaki Y, et al. Hypersensitivity reactions to cisplatin following multiple uncomplicated courses: a report on two cases. J Obstet Gynaecol Res 1997;23: 347-52. (Pubitemid 27393898)
17. Khan A, Hill JM, Grater W, et al. Atopic hypersensitivity to cis-dichlorodiammineplatinum(II) and other platinum complexes. Cancer Res 1975;35:2766-70.
18. Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer 2005;15:13-8. (Pubitemid 40194327)
19. Meyer L, Zuberbier T, Worm M, et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002;20:1146-7. (Pubitemid 34141861)
20. Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 2004;9:546-9. (Pubitemid 39332318)
21. Lim KH, Huang MJ, Lin HC, et al. Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Anticancer Drugs 2004;15:605-7.
22. Mis L, Fernando NH, Hurwitz HI, et al. Successful desensitization to oxaliplatin. Ann Pharmacother 2005;39:966-9. (Pubitemid 40570680)
23. Edmondson DA, Gruling BJ, Urmanski AM, et al. Oxaliplatin hypersensitivity: case report and successful repeat desensitization. Am J Ther 2007;14:116-8. (Pubitemid 46278673)